Search
Search Results
-
Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi)
For many cancer patients, immune checkpoint inhibitors (ICIs) can be life-saving. However, the immune-related adverse events (irAEs) from ICIs can be...
-
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Cutaneous immune-related adverse events encompass a spectrum of dermatological manifestations, including lichenoid reactions, psoriasiform eruptions,...
-
Mechanisms and biomarkers of immune-related adverse events in gastric cancer
Immune-checkpoint inhibitors (ICIs), different from traditional cancer treatment models, have shown unprecedented anti-tumor effects in the past...
-
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but come with severe immune-related adverse events (irAEs)....
-
Immune-Related Adverse Events in Patients with Lung Cancer
Purpose of ReviewImmune checkpoint inhibitors (ICI) have been widely adopted for the treatment of lung cancer since receiving first U.S Food and Drug...
-
Uncovering the Burden of Immune-Related Adverse Events in Immunotherapy: Insights from a Nationally Representative Sample
BackgroundImmune checkpoint inhibitors have shown promising efficacy in multiple malignancies and, therefore, have been increasingly used over the...
-
Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
Identifying patients at increased risk of immune-related adverse events (irAEs) facilitates safe application of immune checkpoint inhibitors (ICIs)....
-
HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
PurposeAs molecules responsible for presenting antigens to T lymphocytes, leukocytes antigens (HLAs) play a vital role in cancer immunology. This...
-
Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series
Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the...
-
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
BackgroundEvidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter...
-
How detection of immune-related adverse events fails during transfer of patients between medical sectors
Immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) in mono- or combination therapy may be acute or delayed, partly...
-
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort
We aim at investigating the association between subclinical autoimmunity and immune-related adverse events (irAEs) in a cohort of patients treated by...
-
Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event
IntroductionT cell activation can lead to osteoporosis and while there are several case reports of fractures occurring after immune checkpoint...
-
Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
PurposeTo evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic...
-
Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases
PurposeImmune checkpoint inhibitor (ICI) therapy can predispose patients to immune-related adverse events (irAEs) and autoimmune disease (AD)...
-
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
BackgroundThe clinical implications of the third dose of coronavirus disease 2019 (COVID-19) vaccines in patients receiving immune checkpoint...
-
Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis
BackgroundCurrently, there is a lack of affordable and accessible indicators that can accurately predict immune-related adverse events (irAEs)...
-
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse...
-
Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
PurposeNeuromuscular immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) have been increasingly recognized as a...
-
Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis
ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of restarting immune checkpoint inhibitors (ICIs) in patients with non-small...
